SavedAdd your journal

Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2017 / Cilt: 23 - Sayı: 2

Hirsutism Acne and Hair Loss: Management of Hyperandrogenic Cutaneous Manifestations of Polycystic Ovary Syndrome

Cenk YAŞA
Özlem DURAL
Ercan BAŞTU
Funda GÜNGÖR UĞURLUCAN
Pages
110–119
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The diagnosis, management, and treatment approaches are described in detail in this review.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Polycystic ovary syndrome is the most common endocrine abnormality that affects reproductive-aged women.
📊
Key Findings & Data:The major determinants of cutaneous manifestations are increased production of androgen and increased tissue availability.
💡
Conclusion & Impact:The diagnosis, management, and treatment approaches are described in detail in this review.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Polycystic ovary syndrome is the most common endocrine abnormality that affects reproductive-aged women. Diagnostic criteria of polycystic ovary syndrome have been established by different societies in recent years, and hyperandrogenism remains as one of the main criteria for diagnosis. Cutaneous man-ifestations of hyperandrogenism include hirsutism, acne and androgenic alopecia and are commonly ob-served in women with polycystic ovary syndrome. The major determinants of cutaneous manifestations are increased production of androgen and increased tissue availability. Cutaneous manifestations of hy-perandrogenism are cosmetic problems, which produce significant emotional distress and psychological morbidity. Treatment includes a combination of combined oral contraceptives, antiandrogens, insulin sensitizers, gonadotropin releasing hormone agonists, topical medications, and cosmetic procedures. The diagnosis, management, and treatment approaches are described in detail in this review.

🔖

Cite This Article

YAŞA, C., DURAL, Ö., BAŞTU, E., UĞURLUCAN, F. G. (2017). Hirsutism Acne and Hair Loss: Management of Hyperandrogenic Cutaneous Manifestations of Polycystic Ovary Syndrome. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 23 - Sayı: 2, 110–119. https://ajindex.com/articles/227752

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Olszewska M1, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005 Sep-Oct;4(5):637-40. 79. Thai K, Sinclair RD. Finasteride for female androgenetic alopecia. Br J Dermatol 2002 Oct;147(4):812-3. 78. Price VH1, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, et al. Lack of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000 Nov;43(5 Pt 1):768-76. 77. Peereboom-Wynia JD1, van der Willigen AH, van Joost T, Stolz E. The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol 1989;69(5):395-8. 76. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005 Mar;152(3):466-73. 75. Lucky AW1, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG. et al. A randomised placebo controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004 Apr;50(4):541-53. 74. Messenger AG, Rundegen J. Minoxidil mechanisms of ac-tion on hair growth. Br J Dermatol. 2004 Feb;150(2):186-94 73. Schmidt JB, Lindmaier A, Trenz A, Schurz B, Spona J. Hormone studies in females with androgenic hair loss. Gynecol Obstet Invest 1991;31(4):235-9. 72. Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalance of polycystic ovaries in wo-men with androgenic alopecia. Eur J Endocrinol 2003 Nov;149(5):439-42. 71. Ozdemir S, Ozdemir M, Gorkemli H, Kiyici A, Bodur S. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand 2010;89(2):199-204. 70. Quinn M, Shinkai K, Pasch L, Kuzmich L, Cedars M, Huddleston H. Prevalance of androgenic alopecia in pa-tients with polycystic ovary syndrome and characteriza-tion of associated clinical and biochemical features. Fertil Steril 2014 Apr;101(4):1129-34 69. Faloia E, Filipponi S, Mancini V, Morosini P, De Pirro R. Treatment with a gonadotrophin-releasing hormone ago-nist in acne or idiopathic hirsutism. J Endocrinol Invest 1993 Oct;16(9):675-7. 68. Costello M1, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contra-ceptive pill for hirsutism, acne, risk of diabetes, cardio-vascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007 Jan 24;(1):CD00555